Cargando…
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
Tumor mutational burden (TMB) is a promising tool to help define patients with triple-negative breast cancer (TNBC) most likely to benefit from immune checkpoint blockade (ICB) therapies. Roughly reflecting the degree of neo-antigens that tumors present to immune cells, TMB associates with multiple...
Autores principales: | O’Meara, Tess A., Tolaney, Sara M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939529/ https://www.ncbi.nlm.nih.gov/pubmed/33747355 http://dx.doi.org/10.18632/oncotarget.27877 |
Ejemplares similares
-
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
por: Sammons, Sarah, et al.
Publicado: (2023) -
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022) -
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2023) -
Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden
por: Qing, Tao, et al.
Publicado: (2020) -
Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)